Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD

BACKGROUND: The safety and efficacy of fixed-dose combination (FDC) of glycopyrronium bromide 12.5 mg/formoterol fumarate 12 mg (GB/FF) twice daily as dry powder inhalers (DPIs) compared to glycopyrronium 50 mg monotherapy (GLY) once daily as DPI in subjects with moderate-to-severe chronic obstructi...

Descripción completa

Detalles Bibliográficos
Autores principales: Salvi, Sundeep, Jain, Manish K., Krishnamurthy, Srikanth, Balki, Akash, Kodgule, Rahul, Tandon, Monika, Bhagat, Sagar, Panchal, Sagar, Khatri, Nishtha, Wu, Wen, Pendse, Amol, Patil, Saiprasad, Barkate, Hanmant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746267/
https://www.ncbi.nlm.nih.gov/pubmed/36629230
http://dx.doi.org/10.4103/lungindia.lungindia_136_22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746267/
https://www.ncbi.nlm.nih.gov/pubmed/36629230
http://dx.doi.org/10.4103/lungindia.lungindia_136_22

Ejemplares similares